Company shares are trading at $3.40 which is significantly lower than $4.21, the 50 day moving average and quite a bit below the 200 day moving average of $6.44. The 50 day moving average went down $-0.81 or -19.33% and the 200 day average went down $-3.04 or -47.19%. Trading was light with 695K shares changing hands on Tuesday. Overall, volume was down 26.55% under the stocks normal daily volume.
Short traders are more bullish on the company recently looking at the change in short interest. The stock recorded a fall in short interest from September 29, 2017 to October 13, 2017 of -7.16%. Short shares decreased 599,416 over that period. Days to cover increased from 5.0 to 9.0 and the short interest percentage is 0.19% as of October 13.
A few notable investment firms have updated their holdings. As of quarter end Ubs Group Ag had sold 502 shares trimming its stake by 62.6%. The value of the investment in ADXS decreased from $7,000 to $2,000 decreasing 71.4% quarter to quarter. As of the end of the quarter Vident Investment Advisory, LLC had acquired a total of 78,100 shares growing its holdings by 71.7%. The value of the investment in (ADXS) went from $890,000 to $1,214,000 a change of $324,000 for the reporting period.
As of the end of the quarter Franklin Street Advisors Inc /nc had acquired 2,000 shares growing its position 3.5%. The value of the company’s investment in Advaxis, Inc. decreased from $375,000 to $250,000 a change of 33.3% quarter over quarter. Cutler Group LP expanded its investment by buying 3,677 shares an increase of 21.7% as of 09/30/2017. Cutler Group LP now controls 20,642 shares with a value of $86,000. The total value of its holdings decreased 21.8%.
In the latest earnings report the EPS was $-2.29 and is estimated to be $-2.23 for the current year with 41,065,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.58 and the next full year EPS is anticipated to be $-2.35.
Advaxis, Inc., launched on February 28, 2002, is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors..